Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity

Shohei Domae, Yoichi Nakamura, Yurika Nakamura, Akiko Uenaka, Hisashi Wada, Masao Nakata, Mikio Oka, Koji Kishimoto, Goichi Tsukamoto, Yasuto Yoshihama, Junji Matsuoka, Akira Gochi, Shigeru Kohno, Takashi Saika, Akira Sasaki, Eiichi Nakayama, Toshiro Ono

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cancer/testis (CT) antigens are expressed in normal germ line tissues and various cancers. They are considered promising target molecules for immunotherapy for patients with various cancers. To identify CT antigens, we performed serological identification of antigens by recombinant expression cloning. The humoral immune response of cancer patients against a newly defined antigen was analyzed. A testicular cDNA library was immunoscreened with serum obtained from a gastric adenocarcinoma patient whose primary cancer had regressed once and most liver metastasies had disappeared transiently. We isolated 55 positive cDNA clones comprising 23 different genes. They included 4 genes with testis-specific expression profiles in the Unigene database, including coiled-coil domain containing 62 (CCDC62). RT-PCR analysis showed that the expression of 2 splice variants of CCDC62 was restricted to the testis in normal adult tissues. In malignant tissues, CCDC62 variant 2 (CCDC62-2) was aberrantly expressed in a variety of cancers, including stomach cancer. A serological survey of 191 cancer patients with a range of different cancers by ELISA revealed antibodies to CCDC62-2 in 13 patients, including stomach cancer. None of the 41 healthy donor serum samples were reactive in the same test. The serum reaction against CCDC62-2 was confirmed by western blot. CCDC62-2 is a CT antigen that is immunogenic in cancer patients.

Original languageEnglish
Pages (from-to)2347-2352
Number of pages6
JournalInternational Journal of Cancer
Volume124
Issue number10
DOIs
Publication statusPublished - May 15 2009

Fingerprint

Testicular Neoplasms
Antigens
Neoplasms
Stomach Neoplasms
Testis
Serum
Humoral Immunity
Gene Library
Germ Cells
Immunotherapy
Genes
Organism Cloning
Stomach
Adenocarcinoma
Complementary DNA
Clone Cells
Western Blotting
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Databases

Keywords

  • Antibody response
  • Cancer/testis antigen
  • CCDC62-2
  • SEREX

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Domae, S., Nakamura, Y., Nakamura, Y., Uenaka, A., Wada, H., Nakata, M., ... Ono, T. (2009). Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. International Journal of Cancer, 124(10), 2347-2352. https://doi.org/10.1002/ijc.24220

Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. / Domae, Shohei; Nakamura, Yoichi; Nakamura, Yurika; Uenaka, Akiko; Wada, Hisashi; Nakata, Masao; Oka, Mikio; Kishimoto, Koji; Tsukamoto, Goichi; Yoshihama, Yasuto; Matsuoka, Junji; Gochi, Akira; Kohno, Shigeru; Saika, Takashi; Sasaki, Akira; Nakayama, Eiichi; Ono, Toshiro.

In: International Journal of Cancer, Vol. 124, No. 10, 15.05.2009, p. 2347-2352.

Research output: Contribution to journalArticle

Domae, S, Nakamura, Y, Nakamura, Y, Uenaka, A, Wada, H, Nakata, M, Oka, M, Kishimoto, K, Tsukamoto, G, Yoshihama, Y, Matsuoka, J, Gochi, A, Kohno, S, Saika, T, Sasaki, A, Nakayama, E & Ono, T 2009, 'Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity', International Journal of Cancer, vol. 124, no. 10, pp. 2347-2352. https://doi.org/10.1002/ijc.24220
Domae S, Nakamura Y, Nakamura Y, Uenaka A, Wada H, Nakata M et al. Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. International Journal of Cancer. 2009 May 15;124(10):2347-2352. https://doi.org/10.1002/ijc.24220
Domae, Shohei ; Nakamura, Yoichi ; Nakamura, Yurika ; Uenaka, Akiko ; Wada, Hisashi ; Nakata, Masao ; Oka, Mikio ; Kishimoto, Koji ; Tsukamoto, Goichi ; Yoshihama, Yasuto ; Matsuoka, Junji ; Gochi, Akira ; Kohno, Shigeru ; Saika, Takashi ; Sasaki, Akira ; Nakayama, Eiichi ; Ono, Toshiro. / Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. In: International Journal of Cancer. 2009 ; Vol. 124, No. 10. pp. 2347-2352.
@article{cf0e0d0136b14d9f8e5541fe3776cce4,
title = "Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity",
abstract = "Cancer/testis (CT) antigens are expressed in normal germ line tissues and various cancers. They are considered promising target molecules for immunotherapy for patients with various cancers. To identify CT antigens, we performed serological identification of antigens by recombinant expression cloning. The humoral immune response of cancer patients against a newly defined antigen was analyzed. A testicular cDNA library was immunoscreened with serum obtained from a gastric adenocarcinoma patient whose primary cancer had regressed once and most liver metastasies had disappeared transiently. We isolated 55 positive cDNA clones comprising 23 different genes. They included 4 genes with testis-specific expression profiles in the Unigene database, including coiled-coil domain containing 62 (CCDC62). RT-PCR analysis showed that the expression of 2 splice variants of CCDC62 was restricted to the testis in normal adult tissues. In malignant tissues, CCDC62 variant 2 (CCDC62-2) was aberrantly expressed in a variety of cancers, including stomach cancer. A serological survey of 191 cancer patients with a range of different cancers by ELISA revealed antibodies to CCDC62-2 in 13 patients, including stomach cancer. None of the 41 healthy donor serum samples were reactive in the same test. The serum reaction against CCDC62-2 was confirmed by western blot. CCDC62-2 is a CT antigen that is immunogenic in cancer patients.",
keywords = "Antibody response, Cancer/testis antigen, CCDC62-2, SEREX",
author = "Shohei Domae and Yoichi Nakamura and Yurika Nakamura and Akiko Uenaka and Hisashi Wada and Masao Nakata and Mikio Oka and Koji Kishimoto and Goichi Tsukamoto and Yasuto Yoshihama and Junji Matsuoka and Akira Gochi and Shigeru Kohno and Takashi Saika and Akira Sasaki and Eiichi Nakayama and Toshiro Ono",
year = "2009",
month = "5",
day = "15",
doi = "10.1002/ijc.24220",
language = "English",
volume = "124",
pages = "2347--2352",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity

AU - Domae, Shohei

AU - Nakamura, Yoichi

AU - Nakamura, Yurika

AU - Uenaka, Akiko

AU - Wada, Hisashi

AU - Nakata, Masao

AU - Oka, Mikio

AU - Kishimoto, Koji

AU - Tsukamoto, Goichi

AU - Yoshihama, Yasuto

AU - Matsuoka, Junji

AU - Gochi, Akira

AU - Kohno, Shigeru

AU - Saika, Takashi

AU - Sasaki, Akira

AU - Nakayama, Eiichi

AU - Ono, Toshiro

PY - 2009/5/15

Y1 - 2009/5/15

N2 - Cancer/testis (CT) antigens are expressed in normal germ line tissues and various cancers. They are considered promising target molecules for immunotherapy for patients with various cancers. To identify CT antigens, we performed serological identification of antigens by recombinant expression cloning. The humoral immune response of cancer patients against a newly defined antigen was analyzed. A testicular cDNA library was immunoscreened with serum obtained from a gastric adenocarcinoma patient whose primary cancer had regressed once and most liver metastasies had disappeared transiently. We isolated 55 positive cDNA clones comprising 23 different genes. They included 4 genes with testis-specific expression profiles in the Unigene database, including coiled-coil domain containing 62 (CCDC62). RT-PCR analysis showed that the expression of 2 splice variants of CCDC62 was restricted to the testis in normal adult tissues. In malignant tissues, CCDC62 variant 2 (CCDC62-2) was aberrantly expressed in a variety of cancers, including stomach cancer. A serological survey of 191 cancer patients with a range of different cancers by ELISA revealed antibodies to CCDC62-2 in 13 patients, including stomach cancer. None of the 41 healthy donor serum samples were reactive in the same test. The serum reaction against CCDC62-2 was confirmed by western blot. CCDC62-2 is a CT antigen that is immunogenic in cancer patients.

AB - Cancer/testis (CT) antigens are expressed in normal germ line tissues and various cancers. They are considered promising target molecules for immunotherapy for patients with various cancers. To identify CT antigens, we performed serological identification of antigens by recombinant expression cloning. The humoral immune response of cancer patients against a newly defined antigen was analyzed. A testicular cDNA library was immunoscreened with serum obtained from a gastric adenocarcinoma patient whose primary cancer had regressed once and most liver metastasies had disappeared transiently. We isolated 55 positive cDNA clones comprising 23 different genes. They included 4 genes with testis-specific expression profiles in the Unigene database, including coiled-coil domain containing 62 (CCDC62). RT-PCR analysis showed that the expression of 2 splice variants of CCDC62 was restricted to the testis in normal adult tissues. In malignant tissues, CCDC62 variant 2 (CCDC62-2) was aberrantly expressed in a variety of cancers, including stomach cancer. A serological survey of 191 cancer patients with a range of different cancers by ELISA revealed antibodies to CCDC62-2 in 13 patients, including stomach cancer. None of the 41 healthy donor serum samples were reactive in the same test. The serum reaction against CCDC62-2 was confirmed by western blot. CCDC62-2 is a CT antigen that is immunogenic in cancer patients.

KW - Antibody response

KW - Cancer/testis antigen

KW - CCDC62-2

KW - SEREX

UR - http://www.scopus.com/inward/record.url?scp=64249143620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249143620&partnerID=8YFLogxK

U2 - 10.1002/ijc.24220

DO - 10.1002/ijc.24220

M3 - Article

C2 - 19165854

AN - SCOPUS:64249143620

VL - 124

SP - 2347

EP - 2352

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -